Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...

Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...

Molecular biology is an ever-changing field, and most significant developments have happened because of changes in plasmid DNA sequencing. A plasmid, a circular and small double-stranded DNA entity ...

The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

The use of performance-enhancing drugs in sports is commonly referred by the term ‘doping’, particularly by those regulatory bodies overseeing sports that have made efforts to fight doping. Through ...

Plasmid DNA lies at the heart of viral and mRNA vector production because it provides the coding sequences for gene-based advanced therapy medicinal products (ATMPs). Its manufacture is therefore ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and ...

Two shortcomings of nonviral gene therapy are a lack of tissue-specific targeting of vectors and low levels of gene transfer. Our laboratory has begun to address these limitations by designing ...